The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations

Gefitinib is an essential drug for NSCLC patients harboring EGFR sensitive mutations. The approved dose 250mg/day is based on limited clinical trials, this research aims to explore the relationship between drug exposure and gefitinib response. C(trough) of 87 NSCLC patients harboring EGFR sensitive...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Sci Rep
Auteurs principaux: Xin, Shuang, Zhao, Yuanyuan, Wang, Xueding, Huang, Yan, Zhang, Jing, Guo, Ying, Li, Jiali, Li, Hongliang, Ma, Yuxiang, Chen, Lingyan, Hu, Zhihuang, Huang, Min, Zhang, Li
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4521154/
https://ncbi.nlm.nih.gov/pubmed/26228025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep12675
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires